MedTrace Logo

Cervical Erector Spinae Block for Shoulder Surgery

NCT04397549 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-05-22

No results posted yet for this study

Summary

Arthroscopic shoulder surgery is often associated with moderate to severe postoperative pain that may interfere with patients' early mobilization, recovery and quality of life.

In addition, by using an effective analgesic technique, a patient may experience less nausea, vomiting and drowsiness after surgery that are associated with the use of opioids to manage postoperative pain. Erector spinae plane block (ESPB) has been used in many different indications for acute pain treatment at different thoracic and lumbar levels. Recently, staining the roots of the brachial plexus has been reported in a cadaveric study of the cervical ESPB (1).

However, there are only few case reports related to efficiency and safety of this newly defined cervical ESPB technique (2) .

The primary objective of this randomized controlled is investigate the post-operative analgesic effectiveness of ultrasound guided single-shot cervical ESPB for patients undergoing arthroscopic shoulder surgery in comparison to those receiving conventional parentheral opioid analgesia alone.

Secondary objective is testing the safety of this newly defined block in terms of incidence of complications.

Conditions

  • Postoperative Pain
  • Shoulder Surgery

Interventions

OTHER

Cervical erector spinae plane block

Cervical erector spinae plane block will be administered before the surgery

DEVICE

Intravenous morphine patient controlled analgesia device

24 hour morphine consumption will be recorded

Sponsors & Collaborators

  • Ataturk University

    collaborator OTHER

  • Konya Necmettin Erbakan Üniversitesi

    lead OTHER

Principal Investigators

  • Alper Kilicaslan, MD, Assoc.Prof · Necmettin Erbakan University Meram Medical Faculty

  • İlker İnce, MD, Assoc.Prof · Ataturk University Medical Faculty

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-15
Primary Completion
2020-09-30
Completion
2020-10-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04397549 on ClinicalTrials.gov